Our strategy of targeting both HER2 and a compensatory pathway was supported by the positive results of a previously conducted phase 3 clinical trial (BOLERO-3, NCT01007942) that evaluated the efficacy of the combination of an mTOR inhibitor and trastuzumab in patients with trastuzumab-resistant advanced breast cancer [31]. The gene discussed is ERBB2; the disease is breast carcinoma.